Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2026)
Crinetics Pharmaceuticals' (CRNX) quarterly FCF Margin came in at 1166.08% in Q1 2026, up 2340899.0% year-on-year from N/an in Q1 2025, and up 22.94% quarter-over-quarter from 1513.28% in Q4 2025.
Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' FCF Margin history runs 10 years deep, the most recent figure standing at 1166.08% for Q1 2026.
- On a quarterly basis, FCF Margin rose 2340899.0% year-over-year to 1166.08% in Q1 2026; TTM through Mar 2026 was 2295.43%, a 3304220.0% increase from a year earlier, with the FY2025 full-year figure at 4915.68%, up 1760963.0% from the prior year.
- FCF Margin climbed to 1166.08% in Q1 2026 per CRNX's latest filing, from 1513.28% in the prior quarter.
- Across five years, FCF Margin topped out at 435.32% in Q1 2022 and bottomed at 74359.44% in Q3 2025.
- The 5-year median for FCF Margin is 7419.2% (2022), against an average of 12070.13%.
- Across the five-year window, FCF Margin plunged 1610819 bps in 2025 and surged 2340899 bps in 2026, its largest moves.
- Year by year, FCF Margin stood at 4770.8% in 2022, then slumped by 153 bps to 12059.83% in 2023, then gained by 3 bps to 11694.24% in 2024, then jumped by 87 bps to 1513.28% in 2025, then increased by 23 bps to 1166.08% in 2026.
- Per Business Quant, the three latest CRNX FCF Margin figures stand at 1166.08% (Q1 2026), 1513.28% (Q4 2025), and 74359.44% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 8.71 Bn | 8.71 Bn | 10.53 Mn | -1,166.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,166.08% |
| Dec 31, 2025 | -1,513.28% |
| Sep 30, 2025 | -74,359.44% |
| Jun 30, 2025 | -8,732.10% |
| Mar 31, 2025 | -24,575.07% |
| Jun 30, 2024 | -11,694.24% |
| Mar 31, 2024 | -8,466.88% |
| Sep 30, 2023 | -12,059.83% |
| Jun 30, 2023 | -4,631.38% |
| Mar 31, 2023 | -1,520.49% |
| Dec 31, 2022 | -4,770.80% |
| Sep 30, 2022 | -8,685.37% |
| Jun 30, 2022 | -6,371.53% |
| Mar 31, 2022 | -435.32% |
| Dec 31, 2021 | -2,125.88% |
| Dec 31, 2020 | 22,471.83% |
| Mar 31, 2020 | -17,309.86% |
| Dec 31, 2019 | -4,197.82% |
| Sep 30, 2019 | -2,694.46% |
| Mar 31, 2019 | -1,849.05% |